Description: Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in 2014 and is headquartered in San Diego, CA.
Home Page: www.poseida.com
PSTX Technical Analysis
9390 Towne Centre Drive
San Diego,
CA
92121
United States
Phone:
858 779 3100
Officers
| Name | Title |
|---|---|
| Dr. Eric M. Ostertag M.D., Ph.D. | Exec. Chairman |
| Mr. Mark J. Gergen J.D. | CEO & Director |
| Ms. Johanna M. Mylet CPA | Chief Financial Officer |
| Mr. Loren Wagner | Sr. VP of Global Operations |
| Dr. Devon J. Shedlock Ph.D. | Chief Scientific Officer of Cell Therapy |
| Ms. Kristin Martin | Chief People & Admin. Officer |
| Sarah Thailing | Sr. Director of Corp. Communications & IR |
| Mr. Harry J. Leonhardt Esq., J.D. | Gen. Counsel, Chief Compliance Officer & Corp. Sec. |
| Ms. Lisa Portale | Sr. VP of Regulatory Affairs |
| Mr. Brent Warner | Pres of Gene Therapy |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.2648 |
| Price-to-Sales TTM: | 3.5246 |
| IPO Date: | 2020-07-10 |
| Fiscal Year End: | December |
| Full Time Employees: | 304 |